NDASUBCUTANEOUSSOLUTION
Approved
Feb 2025
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
1
Data completeness
4/8 — Partial
ONAPGO (apomorphine hydrochloride) by Sumitomo Dainippon Pharma is non-ergoline dopamine agonist with high in vitro binding affinity for the dopamine d4 receptor, and moderate affinity for the dopamine d2, d3, and d5, and adrenergic α1d, α2b, α2c receptors. Approved for parkinson's disease. First approved in 2025.
Drug data last refreshed 18h ago
Mechanism of Action
non-ergoline dopamine agonist with high in vitro binding affinity for the dopamine D4 receptor, and moderate affinity for the dopamine D2, D3, and D5, and adrenergic α1D, α2B, α2C receptors. The precise mechanism of action of ONAPGO as a treatment for Parkinson's disease is unknown, although it is…
Indications (1)
Clinical Trials (1)
Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:
Started Mar 2025
120 enrolled
Parkinson Disease
Why This Matters for Your Career
Worked on ONAPGO at Sumitomo Dainippon Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.